sdsad        Development in the syllabus of Pharmaceutical Marketing & Management that is studied in the Bachelor of Pharmacy course of Bangladeshi Universities.        LOSECTIL stands beside acid survivors        Vitamin D Levels Linked to Parkinson's Symptoms        Keeping the newborn warm at home at winter        Its time to prevent cervical cancer        Huge Rise in CT, MRI, Ultrasound Scan Use: Study        Exercise May Delay Early Aging of People With Diabetes        Alzheimer's Drug Shows Some Promise in Trials        Obesity, Depression Blamed for Daytime Sleepiness Epidemic     

Member Sign In
Forgot Your
Username & Password?

Not a Member?
Please Sign Up Here

Sr. Executive / Executive, Production; THE IBN SINA PHARMACEUTICAL IND LTD

Approval of Brilinta Tablets (ticagrelor) by FDA
Brand Name: Brilinta Tablets
Generic Name: ticagrelor
Company Name: AstraZeneca
Date of Approval: July 20, 2011
Treatmant for: Acute Coronary Syndrome
The U.S. Food and Drug Administration today approved the blood-thinning drug Brilinta (ticagrelor) to reduce cardiovascular death and heart attack in patients with acute coronary syndromes (ACS). ACS includes a group of symptoms for any condition, such as unstable angina or heart attack, that could result from reduced blood flow to the heart. Brilinta works by preventing the formation of new blood clots, thus maintaining blood flow in the body to help reduce the risk of another cardiovascular event.

Brilinta has been studied in combination with aspirin. A boxed warning to health care professionals and patients warns that aspirin doses above 100 milligrams per day decrease the effectiveness of the medication.

In clinical trials, Brilinta was more effective than Plavix in preventing heart attacks and death, but that advantage was seen with aspirin maintenance doses of 75 to 100 milligrams once daily, said Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Products in the FDAs Center for Drug Evaluation and Research.

The boxed warning also says that, like other blood-thinning agents, Brilinta increases the rate of bleeding and can cause significant, sometimes fatal, bleeding. The most common adverse reactions reported by people taking Brilinta in clinical trials were bleeding and difficulty breathing (dyspnea).

Brilinta was approved with a Risk Evaluation and Mitigation Strategy, a plan to help ensure that the drugs benefits outweigh its risks. As part of that plan, the company must conduct educational outreach to physicians to alert them about the risk of using higher doses of aspirin. In addition, Brilinta will be dispensed with a Medication Guide that informs patients of the most important information about the medication. The guide will be distributed each time a patient fills their prescription.

Brilinta is made by AstraZeneca of Wilmington, Del.

For information:

National Heart, Lung and Blood Institute: Heart Attack
Note: To know more please go to the following sources.
Update: 2011-07-21
Source: FDA &
Other FDA Approval
Approval of Natroba Topical Suspension (spinosad) by FDA
Approval of Sylatron (peginterferon alfa-2b) by FDA
Approval of Lazanda Nasal Spray (fentanyl) by FDA
Approval of Daliresp Tablets (roflumilast) by FDA
Approval of Firazyr Injection (icatibant) by FDA
Approval of Ferriprox (deferiprone) by FDA
Approval of Juvisync Tablets (simvastatin and sitagliptin) by FDA
Approval of Onfi (clobazam) by FDA
See all the FDA Approval